BRPI1011857A2 - combinações de clados rrgb pneumocócico - Google Patents

combinações de clados rrgb pneumocócico

Info

Publication number
BRPI1011857A2
BRPI1011857A2 BRPI1011857A BRPI1011857A BRPI1011857A2 BR PI1011857 A2 BRPI1011857 A2 BR PI1011857A2 BR PI1011857 A BRPI1011857 A BR PI1011857A BR PI1011857 A BRPI1011857 A BR PI1011857A BR PI1011857 A2 BRPI1011857 A2 BR PI1011857A2
Authority
BR
Brazil
Prior art keywords
pneumococcal
combinations
rrgb
rrgb clade
clade combinations
Prior art date
Application number
BRPI1011857A
Other languages
English (en)
Inventor
Michèle Barocchi
Monica Moschioni
Paolo Ruggiero
Vega Masignani
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI1011857A2 publication Critical patent/BRPI1011857A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1011857A 2009-06-01 2010-06-01 combinações de clados rrgb pneumocócico BRPI1011857A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21762909P 2009-06-01 2009-06-01
US25442609P 2009-10-23 2009-10-23
US31420310P 2010-03-16 2010-03-16
US31892610P 2010-03-30 2010-03-30
PCT/IB2010/052445 WO2010140119A1 (en) 2009-06-01 2010-06-01 COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES

Publications (1)

Publication Number Publication Date
BRPI1011857A2 true BRPI1011857A2 (pt) 2016-03-29

Family

ID=42557471

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011857A BRPI1011857A2 (pt) 2009-06-01 2010-06-01 combinações de clados rrgb pneumocócico

Country Status (16)

Country Link
US (2) US8609106B2 (pt)
EP (1) EP2437777B1 (pt)
JP (2) JP6008741B2 (pt)
KR (1) KR20120035168A (pt)
CN (1) CN102481354A (pt)
AU (1) AU2010255356A1 (pt)
BR (1) BRPI1011857A2 (pt)
CA (1) CA2764022A1 (pt)
CO (1) CO6470864A2 (pt)
ES (1) ES2531115T3 (pt)
IL (1) IL216696A0 (pt)
MX (1) MX2011012854A (pt)
RU (1) RU2011154363A (pt)
SG (1) SG176285A1 (pt)
WO (1) WO2010140119A1 (pt)
ZA (1) ZA201109046B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
WO2011030218A1 (en) * 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
WO2012072769A1 (en) * 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
DK2822947T3 (en) 2012-03-07 2016-09-19 Glaxosmithkline Biologicals Sa ARGINAL SALTS OF A TLR-7 AGONIST
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
JP2007532656A (ja) * 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
US20060165716A1 (en) * 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
US20090298196A1 (en) * 2005-01-28 2009-12-03 Uwabe Ken-Ichiro Quantitative measurement method for recombinant protein
MX2008010604A (es) * 2006-02-17 2009-03-05 Novartis Ag Purificacion y uso de pilosidades de streptococcus pneumoniae y proteinas pilosas.
EP2063911A2 (en) * 2006-07-26 2009-06-03 Novartis Ag Immunogenic compositions for gram positive bacteria
PL2121011T3 (pl) * 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EA019836B1 (ru) * 2007-11-02 2014-06-30 Те Джонс Хопкинс Юниверсити Композиции многотипных пептидов hpv и способы лечения или предотвращения папилломавирусной инфекции у человека

Also Published As

Publication number Publication date
WO2010140119A1 (en) 2010-12-09
ZA201109046B (en) 2013-05-29
CN102481354A (zh) 2012-05-30
CO6470864A2 (es) 2012-06-29
IL216696A0 (en) 2012-02-29
US20120076814A1 (en) 2012-03-29
RU2011154363A (ru) 2013-07-20
EP2437777A1 (en) 2012-04-11
MX2011012854A (es) 2011-12-16
SG176285A1 (en) 2012-01-30
US20110020385A1 (en) 2011-01-27
CA2764022A1 (en) 2010-12-09
AU2010255356A1 (en) 2011-12-22
JP2015227376A (ja) 2015-12-17
KR20120035168A (ko) 2012-04-13
JP2012528848A (ja) 2012-11-15
US8609106B2 (en) 2013-12-17
ES2531115T3 (es) 2015-03-10
JP6008741B2 (ja) 2016-10-19
EP2437777B1 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
NL301334I2 (nl) vilobelimab
NL301193I2 (nl) tebentafusp
IL252193A0 (en) Greenhouse
EP2498885A4 (en) TOY KREISEL
EP2497655A4 (en) TIRES
BRPI1013989A2 (pt) pneumático
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
BRPI1013720A2 (pt) pneumático
UA21012S (uk) Іграшка
IL216696A0 (en) COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES
DE112010004249A5 (de) Spindelaktor
EP2289713A4 (en) TIRE
BRPI1008070A2 (pt) tricianoboratos
BR112012004964A2 (pt) girocóptero
EP2578812A4 (en) STEAM VALVE
EP2409976A4 (en) GLYCINE TRANSPORTER INHIBITOR
FI20105110A7 (fi) Refraktometri
BRPI1008662A2 (pt) pneumático
EP2418102A4 (en) TIRE
BRPI1007486A2 (pt) pneumático
BRPI1010159A2 (pt) bistuti
NO20090825L (no) Hoyspenttransformator
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
EP2457947A4 (en) TIRE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.